Treatment Adherence With an Oral 9-Month Regimen for Rifampicin-Resistant Tuberculosis in South Africa
Open Access
- 9 February 2026
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (1) , e145-e154
Abstract
Background: Adherence to anti-tuberculosis (TB) therapy is an important determinant of treatment outcome in rifampicin-resistant tuberculosis (RR-TB). Understanding adherence to contemporary treatment regimens in routine care is needed to support implementation in TB programs. We aimed to characterize temporal adherence patterns among people receiving oral treatment for RR-TB. Methods: We conducted a prospective observational cohort study at a referral TB hospital in South Africa. People aged ≥15 years with pulmonary RR-TB starting an oral 9- to 12-month regimen were included. Treatment adherence was measured using a digital pillbox during ambulatory care and with directly observed therapy during hospital care. The primary outcome was proportion of adherence days through 9 months. Latent class group-based trajectory modeling was used to identify temporal adherence patterns. Results: Of 248 participants, 209 (84.3%) had assessable adherence data from the digital pillbox or directly observed therapy. Overall median adherence was 82% (interquartile range [IQR], 63%–98%) with combined measures, and 72% (IQR, 51%–92%) with digital pillbox only. Four distinct adherence patterns were identified. Adherence was 93%–100% in the first month. Two groups, representing 136 (65.1%) individuals, had small reductions in adherence over time, separated by higher and lower early adherence. In the other 2 groups, there was a 50% reduction in adherence by month 3 (48/209 [23.0%]) and month 6 (25/209 [12.0%]), respectively. Lower adherence over time was associated with having exclusive ambulatory care, treatment with the shorter regimen only, and age <40 years. Conclusions: Treatment adherence declined over time in distinct temporal patterns. Group characteristics could identify individuals who may benefit from enhanced treatment support.Keywords
Funding Information
- South African Medical Research Council
- Wellcome Discovery Research Platform in Infection
- Hjärt-Lungfonden
- Svenska Läkaresällskapet
- Bill and Melinda Gates Foundation
- Wellcome Trust
- Department of Science and Technology, Ministry of Science and Technology, India
- National Research Foundation
This publication has 26 references indexed in Scilit:
- Characterizing Treatment Adherence Trajectories in the endTB Multisite Cohort of Drug-Resistant Tuberculosis Patients: An Application of Group-Based Trajectory ModelingClinical Infectious Diseases, 2025
- Treatment Outcomes With an Oral Short Course Regimen for Rifampicin-resistant Tuberculosis in a High HIV Prevalence, Programmatic Setting in South AfricaClinical Infectious Diseases, 2025
- Risk factors of treatment interruptions among drug-sensitive and drug-resistant pulmonary tuberculosis patients - A study from South Delhi, New Delhi, IndiaIndian Journal of Tuberculosis, 2024
- Using a medication event monitoring system to evaluate self-report and pill count for determining treatment completion with self-administered, once-weekly isoniazid and rifapentineContemporary Clinical Trials, 2023
- Outcomes and adherence of shorter MDR TB regimen in patients with multidrug resistant tuberculosisIndian Journal of Tuberculosis, 2022
- Measuring tuberculosis medication adherence: a comparison of multiple approaches in relation to urine isoniazid metabolite testing within a cohort study in IndiaOpen Forum Infectious Diseases, 2021
- Outcome of community-initiated treatment of drug-resistant tuberculosis patients in Lagos, NigeriaTransactions of the Royal Society of Tropical Medicine and Hygiene, 2021
- Electronic Dose Monitoring Identifies a High-Risk Subpopulation in the Treatment of Drug-resistant Tuberculosis and Human Immunodeficiency VirusClinical Infectious Diseases, 2020
- A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosisNature Medicine, 2018
- Effects of Treatment Interruption Patterns on Treatment Success Among Patients With Multidrug-Resistant Tuberculosis in Armenia and AbkhaziaThe Journal of Infectious Diseases, 2014